奧聯電子(300585.SZ)擬5600萬元收購一曜生物20%股權
格隆匯9月3日丨奧聯電子(300585.SZ)公佈,公司於2020年9月3日與上海一曜生物技術(集團)有限公司(以下簡稱“一曜集團”,為廣西一曜生物科技有限公司控股股東)、廣西一曜生物科技有限公司(以下簡稱“一曜生物”)、莊賢韓(為一曜生物實際控制人)簽署了《關於廣西一曜生物科技有限公司之股權轉讓協議》,公司擬以自有資金5600.00萬元收購一曜集團持有的一曜生物20.00%股權。
一曜生物主營業務為動物疫苗的研發、生產、銷售和寵物醫療服務,擬生產的主要產品為“狂犬病滅活疫苗(PV/BHK-21株)”。目前,該產品已經取得《新獸藥註冊證書》,產品生產線處於調試過程中,尚未正式投產。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.